<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892384</url>
  </required_header>
  <id_info>
    <org_study_id>1289.18</org_study_id>
    <nct_id>NCT01892384</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of BI 409306 in Patients With Schizophrenia</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Patients With Schizophrenia (Randomized, Parallel-group, Double-blind, Placebo-controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of&#xD;
      BI 409306 in schizophrenic patients following oral administration of multiple low, medium,&#xD;
      and high doses over 14 days.&#xD;
&#xD;
      A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI&#xD;
      409306 in schizophrenic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants (%) with drug-related adverse events</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, ss</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BI 409306 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>low dose</description>
    <arm_group_label>BI 409306 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>medium dose</description>
    <arm_group_label>BI 409306 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>high dose</description>
    <arm_group_label>BI 409306 dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with established diagnoses of schizophrenia (per Diagnostic and Statistical&#xD;
             Manual of Mental Disorders (DSM-IV)) with the following clinical features:&#xD;
&#xD;
               1. Clinically stable and are in the residual (non-acute) phase of their illness for&#xD;
                  at least 8 weeks.&#xD;
&#xD;
               2. Maintained on current antipsychotic medications and current dose for at least 8&#xD;
                  weeks.&#xD;
&#xD;
               3. Have no more than a moderate severity rating on hallucinations and delusions&#xD;
                  (e.g. Brief Psychiatric Rating Scale (BPRS) Hallucinatory Behavior or Unusual&#xD;
                  Thought Content item score &lt; or =4).&#xD;
&#xD;
               4. Have no more than a moderate severity rating on positive formal thought disorder&#xD;
                  (e.g. BPRS Conceptual Disorganization item score &lt; or =4).&#xD;
&#xD;
               5. Have no more than a moderate severity rating on negative symptoms (Positive and&#xD;
                  Negative Syndrome Scale negative syndrome total score &lt;15).&#xD;
&#xD;
               6. Have a minimal level of extrapyramidal symptoms (e.g. Simpson-Angus Scale total&#xD;
                  score &lt; 6) and depressive symptoms (e.g. Calgary Depression Scale total score &lt;&#xD;
                  10).&#xD;
&#xD;
          2. Male or female patients age &gt; or = 18 and &lt; or =55 years.&#xD;
&#xD;
          3. Patients must exhibit reliability and physiologic capability to comply with all&#xD;
             protocol procedures.&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP and the local legislation. If the patient needs a legal&#xD;
             representative, then this legal representative must give written consent as well.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patient treated with more than one antipsychotic or not stabilized on antipsychotic&#xD;
             treatment, or having had electroconvulsive therapy within the last 30 days&#xD;
&#xD;
          2. Patient's cognitive impairment severity compromises the validity of the cognitive&#xD;
             outcome measures, in the clinical judgment of the investigator.&#xD;
&#xD;
          3. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,&#xD;
             aborted attempt, or preparatory acts or behavior).&#xD;
&#xD;
          4. Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale&#xD;
             (C-SSRS) in the past 3 months (i.e. active suicidal thought with intent but without&#xD;
             specific plan, or active suicidal thought with plan and intent).&#xD;
&#xD;
          5. Any finding of the medical examination (including BP, PR and ECG) or laboratory value&#xD;
             deviating from normal and of clinical relevance in the judgment of the investigator.&#xD;
&#xD;
          6. Any evidence of a clinically relevant concomitant disease.&#xD;
&#xD;
          7. History or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal,&#xD;
             hepatic, renal, respiratory, cardiovascular, metabolic, immunological, haematological&#xD;
             or hormonal disorders.&#xD;
&#xD;
          8. Female patients that are of child-bearing potential or currently breastfeeding.&#xD;
&#xD;
          9. Known history, or new diagnosis per screening labs, of HIV infection.&#xD;
&#xD;
         10. History of neurologic (e.g. stroke, seizure without a clear and resolved etiology,&#xD;
             concussion accompanying loss of consciousness) or psychiatric condition that the&#xD;
             investigator deems may interfere with interpretability of data&#xD;
&#xD;
         11. History of malignancy within the last 5 years, except for basal cell carcinoma.&#xD;
&#xD;
         12. Planned elective surgery requiring general anaesthesia, or hospitalisation for more&#xD;
             than 1 day during the study period.&#xD;
&#xD;
         13. Any other clinical condition that, in the opinion of the investigator, would&#xD;
             jeopardize a patient's safety while participating in this clinical trial.&#xD;
&#xD;
         14. Significant history of drug dependence or abuse (including alcohol, as defined in&#xD;
             Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) or in the opinion of&#xD;
             the investigator) within the last two years prior to informed consent, or a positive&#xD;
             urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana&#xD;
             at screening.&#xD;
&#xD;
         15. Participation in another trial with an investigational drug or procedure within 30&#xD;
             days prior to screening or previous participation in any BI 409306 study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.18.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 409306</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

